Medicine
Radiation Therapy Techniques for Pediatric Medulloblastoma
Quick fact
Modern proton therapy can reduce the radiation dose to the inner ear and the brain's temporal lobes by over 90% compared to standard X-ray therapy, dramatically lowering the risk of hearing loss and cognitive impairment.
Why this is interesting
When a child is diagnosed with a brain tumor, doctors must deliver radiation to the entire head and spine—but doing so risks the child's developing brain. How can radiation cure yet minimize lifelong damage?
Read the full explanation
Understanding Radiation Therapy Techniques for Pediatric Medulloblastoma
Medulloblastoma is a fast-growing tumor that sits in the cerebellum and tends to spread through the cerebrospinal fluid (CSF) that bathes the brain and spinal cord. That is why, even though the tumor itself is localized, radiation must be given to the entire neuraxis—the whole brain and spinal cord—a technique called craniospinal irradiation (CSI). Traditionally, X-ray (photon) beams were used for CSI. But these beams travel through the body, depositing energy in all tissues along the path, including the inner ear, the pituitary gland, and the brain's memory and learning centers. In a child's still-developing nervous system, this can cause significant late effects: hearing loss, hormonal deficiencies, and impaired cognition. The challenge is to deliver a lethal dose to cancer cells anywhere in the CNS while sparing as much healthy tissue as possible. Oncologists use several techniques to do this. One is intensity-modulated radiation therapy (IMRT), which shapes the beam intensity to conform closely to the target, reducing dose to nearby organs at risk. Another is proton therapy, a particle technique that exploits the 'Bragg peak' physics: protons deposit most of their energy at a precisely controlled depth and then stop, with virtually no exit dose. This means that beyond the tumor, there is almost no radiation. Additionally, a 'boost' dose is given to the tumor bed—the area where the tumor was removed—to ensure high dose to any microscopic residual cells. The total dose and the need for boost depend on the child's risk group: average-risk (tumor fully resected, no metastasis) or high-risk (residual tumor or spread).
A deeper explanation
The mechanism of radiation therapy lies in its ability to damage the DNA of rapidly dividing cells. Radiation creates free radicals and breaks DNA strands, triggering cell death. Because cancer cells divide more frequently than most normal tissues, they are more susceptible. However, in the developing brain, normal neural progenitor cells also divide actively, making them vulnerable. The planning process relies on imaging (CT and MRI) to delineate the target volumes—the tumor bed and the entire subarachnoid space—and organs at risk. Dosimetrists use sophisticated algorithms to optimize beam angles and intensities. For IMRT, multiple photon beams are shaped and modulated by a multileaf collimator, creating a sharp dose gradient. Still, each photon beam passes through the body, giving what is called 'exit dose' to structures beyond the target. Proton therapy overcomes this by using charged particles that travel a finite distance. As protons slow down, they deposit a sharp peak of energy—the Bragg peak—at a depth determined by their energy. The clinician can 'spread' the Bragg peak to cover the target, but the defining feature is that essentially no dose is delivered beyond the target. This means the cochlea, the optic chiasm, the hypothalamus, and the developing brain can all be spared from radiation that would otherwise damage them. But proton therapy is not without complexity. It is more sensitive to anatomical changes (patient movement, weight gain) and requires careful quality assurance. Moreover, the cost and availability are limited. Understanding these techniques is crucial because the goal is not just to cure the cancer, but to allow the child to live a long and high-quality life. Radiation oncologists must balance the risk of recurrence (which is high if dose is inadequate) against the risk of late effects that can impair the child's learning, growth, and endocrine function. Modern techniques have enabled dose de-escalation for average-risk patients, further reducing toxicity, without compromising survival.